Form 4: Arcus Biosciences CFO Sells Shares Under 10b5-1 Plan

Arcus Biosciences CFO Robert C. Goeltz II sold 5,000 shares of common stock for $25 per share on November 26, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Robert C. Goeltz II, Chief Financial Officer of Arcus Biosciences, Inc. (RCUS), reported a transaction involving the company's common stock.
• On November 26, 2025, Mr. Goeltz II disposed of 5,000 shares of common stock.
• The shares were sold at a price of $25 per share.
• Following this transaction, Mr. Goeltz II beneficially owns 87,138 shares of Arcus Biosciences common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person.

Sentiment

Score: 5

Explanation: The sale of shares by the CFO was executed under a pre-arranged 10b5-1 trading plan, which typically indicates a planned liquidity event rather than a reaction to new material non-public information. This generally results in a neutral sentiment as it's a routine, pre-scheduled transaction.

Negatives

• Chief Financial Officer Robert C. Goeltz II disposed of 5,000 shares of Arcus Biosciences common stock.

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted in various ways, though the execution under a Rule 10b5-1 plan mitigates concerns about immediate negative sentiment, as it suggests a pre-planned financial management strategy rather than a reaction to new company developments.

Key Dates

Recommendation

The sale of shares by the Chief Financial Officer was conducted under a pre-established Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new material information. Such routine insider sales generally do not signal a fundamental shift in company prospects and therefore do not warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Stock Sale, CFO, Robert C. Goeltz II, 10b5-1 Plan, Common Stock